NKTX
Nkarta IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$164.68M
P/E Ratio
—
EPS
$-1.41
Beta
0.67
52W High
$2.81
52W Low
$1.48
50-Day MA
$2.29
200-Day MA
$2.08
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Nkarta Inc
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and markets cell therapies for the treatment of cancer. The company is headquartered in South San Francisco, California.
Fundamentals
| Revenue (TTM) | 385 |
| Gross Profit (TTM) | $-36.22M |
| EBITDA | $-106.64M |
| Operating Margin | 0.00% |
| Return on Equity | -28.90% |
| Return on Assets | -16.00% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $4.39 |
| Price-to-Book | 0.53 |
| Price-to-Sales (TTM) | 1000000.00 |
| EV/Revenue | 1000000.0 |
| EV/EBITDA | 0.95 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $71.29M |
| Float | $56.63M |
| % Insiders | 4.96% |
| % Institutions | 78.00% |
Analyst Ratings
Consensus ($14.20 target)
1
Strong Buy5
BuyData last updated: 4/9/2026